Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epoetin Alfa in Anemic Patients with MDS
NCT00695396Phase 3Terminated
- Sponsor
- Johnson & Johnson
- Start
- Jun 2008
- Primary completion
- Jan 2010
- Modality
- Biologic, rProtein (Recombinant Protein)
01
Overview
A Phase 3 trial of epoetin alfa in myelodysplastic syndrome (MDS), sponsored by Johnson & Johnson. Started Jun 2008; status: terminated.
02
Drugs
epoetin alfa
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00695396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00695396.